Übersichtsartikel

 

 

ab 2014

  1. Riechers A, Bosserhoff AK: MIA in melanoma diagnostics and therapy – a small protein is looming large. Exp Dermatol 23:12-14 (2014) IF 3.6

  2. Kappelmann M, Bosserhoff AK*, Kuphal S: AP-1/c-Jun transcription factors: Regulation and function in malignant melanoma. Eur J Cell Biol 93 (1-2): 76-81 (2014) (*: corresponding author) IF 3.2

  3. Luo C, Weber CEM, Osen W, Bosserhoff AK, Eichmüller SB: The role of microRNAs in melanoma. Eur J Cell Biol 93 (1-2): 11-22 (2014) IF 3.2

  4. Bosserhoff AK: Im Kampf gegen das Melanom von embryonalen Zellen lernen. Biotechnologie in Bayern, p. 60-61 (2014)

  5. Mione M, Bosserhoff A: MicroRNAs in melanocyte and melanoma biology. Pigment Cell Melanoma Res 28 (3): 340-354 (2015) IF 4.6

  6. Dietrich P, Bosserhoff AK: Modifying microRNAs - another piece of the melanoma puzzle. Pigment Cell Melanoma Res [Epub ahead of print] (2015) IF 4.6

2013 und älter

  1. Bosserhoff AK, Golob M, Buettner R, Landthaler M, Hein R: [MIA ("melanoma inhibitory activity"). Biological functionsand clinical relevance in malignant melanoma]. Hautarzt 49: 762-769 (1998) IF 0.5

  2. Bosserhoff AK, Gläßl A, Stolz W, Buettner R: Detection of Telomerase Activity in Skin, Melanocytic Nevi, and Melanoma by Telomerase PCR ELISA. PCR Application Manual 2nd Edition (Roche Molecular Biochemicals) Chapter 10, 256-259 (1999)

  3. Bosserhoff AK: MIA: Ein wertvoller Marker in der Nachsorge des malignen Melanoms. Empfehlung zur Diagnostik, Therapie und Nachsorge. Maligne Melanome, Zuckschwerdt Verlag München (2000)

  4. Bosserhoff AK, Buettner R, Hellerbrand C: Use of capillary electrophoresis for high throughput screening in biomedical applications. A minireview. Comb Chem High Throughput Screen 3: 455-466 (2000) IF 2.5

  5. Bosserhoff AK, Hellerbrand C, Buettner R: [Clinical and genetic aspects of hereditary hemochromatosis]. Pathologe 22: 191-196 (2001) IF 0.6

  6. Bosserhoff AK, Buettner R: Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol 17: 289-300 (2002) IF 1.8

  7. Poser I, Bosserhoff AK: Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol 19: 173-188 (2004) IF 1.9

  8. Kuphal S, Bauer R, Bosserhoff AK: Integrin signaling in malignant melanoma. Cancer Metastasis Rev 24: 195-222 (2005) IF 8.0

  9. Bosserhoff AK: Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression. Pigment Cell Res 18: 411-416 (2005) IF 2.7

  10. Hein R, Bosserhoff A, Ring J: Tumormarker beim Malignen Melanom. Deutsches Ärzteblatt 103: A493 - A498 (2006)

  11. Bosserhoff AK: Novel biomarkers in malignant melanoma. Clin Chim Acta 367: 28-35 (2006) IF 2.2

  12. Bosserhoff AK: Meeting Report: Perspectives in Melanoma IX. Expert Reviews of Dermatology 1: 9-11 (2006)

  13. Bosserhoff AK: Integrins in therapy. Expert Opinion on Therapeutic Patents 16: 963-975 (2006) IF 1.5

  14. Bosserhoff AK: Melanoma Inhibitory Protein (MIA1). AfCS-Nature Molecule Pages (2006). (doi:10.1038/mp.a003970.01)

  15. Rothhammer T, Bosserhoff AK: Epigenetic events in malignant melanoma. Pigment Cell Res 20: 92-111 (2007) IF 4.3

  16. Wild PJ, Meyer S, Landthaler M, Hofstaedter F, Bosserhoff AK: A potential predictive marker for response to interferon in malignant melanoma. J Dtsch Dermatol Ges 5: 456-459 (2007)

  17. Stoll R, Bosserhoff A: Extracellular SH3 domain containing proteins--features of a new protein family. Curr Protein Pept Sci 9: 221-226 (2008) IF 3.0

  18. Mueller DW, Bosserhoff AK: Role of miRNAs in the progression of malignant melanoma. Br J Cancer 101: 551-556 (2009) IF 4.9

  19. Muller DW, Bosserhoff AK: miR(acle)s - new players in the regulation of known suspects. Pigment Cell Melanoma Res 22: 525-526 (2009) IF 4.6

  20. Kuphal S, Bosserhoff A: Recent progress in understanding the pathology of malignant melanoma. J Pathol 219: 400-409 (2009) IF 5.1

  21. Wenke AK, Bosserhoff AK: Roles of AP-2 transcription factors in the regulation of cartilage and skeletal development. FEBS J 277: 894-902 (2010) IF 3.1

  22. Kuphal S, Meier F, Bosserhoff AK: Individualisierte Therapie beim Malignen Melanom. Im Focus Onkologie 13: 66 – 73e (2010)

  23. Mueller DW, Bosserhoff AK: The evolving concept of "melano-miRs"- microRNAs in melanomagenesis. Pigment Cell Melanoma Res 23: 620-626 (2010) IF 4.3

  24. Kuphal S, Meier F, Bosserhoff AK: Individualisierte Therapie beim Malignen Melanom. Hautnah Dermatologie 3: 80-85e (2011)

  25. Bosserhoff A, Hellerbrand C: Obesity and Fatty liver are 'grease' for the machinery of hepatic fibrosis. Dig Dis 29: 377-383 (2011) IF 1.0

  26. Smalley KS, Aplin AE, Flaherty KT, Hoeller C, Bosserhoff AK, Haass NK, Bosenberg M, Ribas A, Barnhill R, Kudchadkar R, Messina JL: Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res 25: E1-E11 (2011) IF 4.8

  27. Völler D, Bosserhoff AK: MicroRNAs and signaling, complex interaction by feedback loops. Pigment Cell Melanoma Res 25: 128-130 (2012) IF 4.8

  28. Kuphal S, Bosserhoff AK: E-cadherin cell-cell communication in melanogenesis and during development of malignant melanoma. Arch Biochem Biophys 524: 43-47 (2012) IF 3.0

  29. Schmidt J, Riechers A, Bosserhoff AK: MIA - a New Target Protein for Malignant Melanoma Therapy. Histol Histopathol 28: 421-426 (2013) IF 2.5

  30. Canady J, Karrer S, Fleck M, Bosserhoff AK: Fibrosing connective tissue disorders of the skin: molecular similarities and distinctions. J Dermatol Sci 70: 151-158 (2013) IF 3.7

  31. Völler D, Ott C, Bosserhoff AK: MicroRNAs in malignant melanoma. Clin Biochem (special issue: miRNAs in Clinical Practice) 46 (10-11): 909-917 (2013) IF 2.1

  32. Kuphal S, Bosserhoff A: miR networks in melanoma - more to come! Pigment Cell Melanoma Res 26: 292-293 (2013) IF 5.8